Cyclerion Therapeutics, Inc. (CYCN) has a negative trailing P/E of -3.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -31.08%.
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.4 | 0.00 | 0.00 | 0.00 | - |
| 2017 | -3.6 | -0.08 | -39.84 | 0.00 | - |
| 2018 | -3.0 | -0.13 | -32.68 | 0.00 | - |
| 2019 | -0.6 | -0.13 | 0.76 | 16.52 | - |
| 2020 | -1.2 | 0.03 | 1.56 | 40.52 | - |
| 2021 | -1.3 | 0.03 | 1.40 | 20.28 | - |
| 2022 | -0.6 | 0.03 | 2.73 | 95.99 | - |
| 2023 | -1.5 | 0.03 | 0.69 | 0.00 | - |
| 2024 | -2.7 | 0.03 | 0.92 | 4.05 | - |
| 2025 | -1.2 | 0.12 | 0.45 | 1.97 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-46.39 | $0.00 | $-63.55M | - |
| 2017 | $-68.80 | $0.00 | $-93.92M | - |
| 2018 | $-84.42 | $0.00 | $-115.25M | - |
| 2019 | $-88.37 | $4.51M | $-120.98M | -2684.2% |
| 2020 | $-47.80 | $2.3M | $-72.67M | -3165.1% |
| 2021 | $-26.40 | $3.32M | $-51.66M | -1556.1% |
| 2022 | $-20.15 | $297K | $-43.78M | -14742.1% |
| 2023 | $-8.99 | $0.00 | $-21.02M | - |
| 2024 | $-1.21 | $2M | $-3.06M | -152.9% |
| 2025 | $-1.09 | $2.07M | $-3.53M | -170.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.20 | $-1.20 – $-1.20 | $90.33M | $90.33M – $90.33M | 1 |
| 2027 | $-0.99 | $-0.99 – $-0.99 | $586.14K | $586.14K – $586.14K | 1 |
